Replies to post #4011 on Amarin Corp Plc (AMRN)

[Biobillionair]

To add to SR, Amarin has specific patents related to non active ingredients in capsule preserving the active form. The "generic" document DEMANDS the same inactive ingredients thus validating the Patent until 2030. So it's more like a 17 yr NCE designation if capsule patent holds. Also note the separation between Lovaza's alpha-tocopherol and Amarins just "tocopherol". The USP also changed Icosapent Ethyl to Icosapent Ethyl CAPSULE.

Good luck defeating a patent that both the USP and FDA support.

[linhdtu]

Tradewinds, generic competition intensity will depend on the degree of success.

If V doesn't sell in the Bs, I am guessing there will be less interest. Remember when there is a will , there is a way.

My opinion is based on my experience with mnta. Biologic generics which is the game of momenta is extremely hard to copy and yet because they are all blockbusters (like Humira for ex) the generic space is already very crowded especially in Europe.

Momenta tries for substitutability where as their competitions go for the biosimilar pathway.

Point is if you are successful enough there will always be people trying to eat your lunch. How good these barriers are nobody knows until the time comes.